Related Experiment Video

Updated: Jul 10, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated

J Zhou1, M Pan, Z Xie

  • 1Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Leukemia
|October 19, 2007
PubMed

Insights

ABT-869 effectively targets acute myeloid leukemia (AML) with FLT3-ITDs by downregulating cell cycle proteins and inducing apoptosis. Combination therapy with chemotherapy shows synergistic effects, warranting clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Internal tandem duplications (ITDs) in the fms-like tyrosine kinase 3 (FLT3) receptor are key drivers in acute myeloid leukemia (AML) pathogenesis.
  • FLT3-ITDs represent a critical therapeutic target for novel AML treatments.

Purpose of the Study:

  • To investigate the therapeutic effects of ABT-869 on AML cells with FLT3-ITDs.
  • To evaluate the synergistic potential of combining ABT-869 with standard chemotherapeutic agents.
  • To elucidate the molecular mechanisms underlying ABT-869's efficacy and combination therapy.

Main Methods:

  • Treatment of AML cell lines and primary samples with ABT-869 and chemotherapy agents (cytarabine, doxorubicin).
  • Assessment of cell cycle regulators (cyclins, p21, p27), apoptosis markers (Bcl-xL, BAK, BID, BAD), and gene expression using low-density arrays.
  • Validation in MV4-11 xenograft models and manipulation of CCND1 and c-Mos expression via short hairpin RNAs.

Main Results:

  • ABT-869 downregulates cyclins D and E, upregulates p21 and p27, and induces apoptosis by modulating Bcl-xL, BAK, BID, and BAD.
  • Significant sequence-dependent synergism was observed between ABT-869 and cytarabine or doxorubicin in AML cells.
  • Combination therapy led to downregulation of cell cycle and MAPK pathway genes, with CCND1 and c-Mos being key inhibited targets.

Conclusions:

  • ABT-869 demonstrates potent anti-leukemic activity through cell cycle arrest and apoptosis induction.
  • Sequence-dependent combination therapy with ABT-869 and chemotherapy exhibits significant synergistic effects in AML.
  • Targeting CCND1 and c-Mos enhances ABT-869 sensitivity, supporting their role in combination strategies and warranting clinical investigation.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...